2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5895 Disruption of the interferon-gamma axis limits chimeric antigen receptor T cell efficacy against acute myeloid leukemia

Nat Murren, BS, Isaac King2, Lauren Mahoney3, Jarron Roy4, Otto Kletzien, PhD5, Maddy Collins6, Sarah Geffe7, Luke Kalcheim8, Rebecca Richards, MD, PhD9
1 University of Wisconsin-Madison, Madison, Wisconsin, United States
2 University of Wisconsin-Madison, Madison, Wisconsin, United States
3 University of Wisconsin-Madison, Madison, Wisconsin, United States
4 University of Wisconsin-Madison, Madison, Wisconsin, United States
5 University of Wisconsin-Madison, Madison, Wisconsin, United States
6 University of Wisconsin-Madison, Madison, Wisconsin, United States
7 University of Wisconsin-Madison, Madison, Wisconsin, United States
8 University of Wisconsin-Madison, Madison, Wisconsin, United States
9 University of Wisconsin-Madison, Madison, Wisconsin, United States

Despite the success of chimeric antigen receptor (CAR) T cell therapy for B cell acute lymphoblastic leukemia (B-ALL), its translation to acute myeloid leukemia (AML) has been limited by poor efficacy and significant toxicity. Interferon-gamma (IFNγ) blockade with emapalumab has recently emerged as a promising strategy to mitigate CAR T cell-related toxicities in B cell malignancies, based on evidence that IFNγ is largely dispensable for optimal CAR T cell activity in B-ALL. Whether IFNγ signaling is similarly dispensable in the AML context remains unclear. In solid tumor models, disruption of IFNγ signaling has been associated with increased tumor resistance to CAR T cell killing, partially attributed to reduced expression levels of adhesion molecule ICAM-1. IFNγ is known to regulate expression of ICAM-1 and apoptotic death receptors like Fas, both of which are commonly expressed on AML. Thus, we hypothesized that unlike in B-ALL, an intact IFNγ axis is required for CAR T cells to effectively kill AML.

To investigate this, we engineered Nalm-6 B-ALL cells to express CD123 (N6-123) and AML cell lines to express CD19. These cell lines were co-cultured with CD19 or CD123 CAR T cells with and without IFNγ inhibition by pharmacologic blockade or IFNγ genetic knockout (IFNγKO) in serial re-challenge cytotoxicity assays. Tumor growth was quantified using Incucyte live-cell imaging. Neither pharmacologic blockade nor IFNγ knockout impacted CD123 CAR T cells cytotoxicity against B-ALL N6-123 cells. In contrast, disruption of IFNγ impaired both CD123 and CD19 CAR T cell killing of multiple AML cell lines. We validated these data in co-cultures with primary leukemia samples, using LDH release to quantify cytotoxicity. Again, IFNγ blockade significantly reduced CD123 CAR T cell cytotoxicity against primary AML but had no effect on CD19 CAR T cells against primary B-ALL. In vivo, NSG mice were engrafted with AML cell line OCI-AML3 then treated with wild-type (WT) or IFNγKO CD123 CAR T cells, and tumor burden was monitored with bioluminescence imaging. These data similarly demonstrated a trend toward IFNγ dependence, with mice treated with IFNγKO CAR T cells displaying reduced tumor control compared to WT CAR T cells.

Mechanistically, we hypothesized that IFNγ promotes AML susceptibility to CAR T cell killing by remodeling the tumor cell surface phenotype. Therefore, utilizing flow cytometry, we investigated the surface expression of CD123, ICAM-1, and Fas on AML and B-ALL cell lines both during co-culture and after exposure to AML-CAR T conditioned media. Improved cytotoxicity of CD123 CAR T cells against AML correlated with IFNγ-mediated CD123 and ICAM-1 upregulation during and after co-culture. Exposure to supernatant from CAR T cell co-cultures also induced CD123, ICAM-1, and Fas upregulation on AML cell lines. In both cases, the upregulation of these key molecules on AML was either significantly reduced (ICAM-1 and Fas) or completely diminished (CD123) by IFNγ blockade, whereas expression on N6-123 cells remained unaffected. To assess its contribution to CAR T cell cytotoxicity, ICAM-1 function was inhibited with a blocking antibody, alone or in combination with IFNγ blockade. ICAM-1 blockade significantly reduced CD123 CAR T cell killing of AML but not B-ALL, and combined blockade of IFNγ and ICAM-1 further exacerbated this effect. Finally, AML and B-ALL cell lines were incubated with exogenous IFNγ and co-cultured with CD123 CAR T cells for cytotoxicity assays and avidity measurements. The addition of exogenous IFNγ improved CAR T cell cytotoxicity and avidity against AML but not B-ALL, coinciding with increased expression of CD123, ICAM-1, and Fas expression only on AML.

Our data demonstrate that disruption of the IFNγ axis impedes anti-AML CAR T cell activity and prevents upregulation of target antigen CD123 and immune synapse and apoptotic mediators ICAM-1 and Fas on AML cells. These findings identify IFNγ as a critical mediator of CAR T cell efficacy in AML by promoting both target antigen expression and stable CAR T cell-tumor interactions. Our results suggest that therapeutic IFNγ blockade, including with emapalumab, may compromise CAR T cell responses in AML and should be approached with caution in this disease context. Altogether, our data highlight core differences between AML and B-ALL susceptibility to CAR T cells and highlight the importance of defining a tumor-specific molecular microenvironment.

Nat Murren, BS: No relevant conflicts of interest to declare.